

RECEIVED  
CENTRAL FAX CENTER

OCT 26 2005

Appln No.: 10/605,498

Amendment Dated: October 26, 2005

Reply to Office Action of September 7, 2005

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-13. (canceled)

14. (currently amended) A pharmaceutical composition comprising a therapeutic agent effective to reduce the amount of active hsp27 in cancerous cells exposed to the therapeutic agent, and a pharmaceutically acceptable carrier, wherein the therapeutic agent is an oligonucleotide having a sequence complementary to a portion of Seq. ID No. 91 and wherein the oligonucleotide is an antisense oligonucleotide comprising the sequence of bases as set forth in any one of Seq. ID Nos. 1 to 82, or an siRNA comprising the sequence of bases as set forth in any one of Seq. ID Nos. 83-90.

15. (canceled)

16. (original) The composition of claim 15, wherein the antisense oligonucleotide has backbone modifications to provide resistance against nucleic acid digestion *in vivo*.

17. (currently amended) The composition of claim 15, wherein oligonucleotide is an antisense and the oligonucleotide has a length of from 12 to 35 nucleotides.

18. (withdrawn, currently amended) The composition of claim 14+7, wherein the antisense oligonucleotide comprises the sequence a consecutive series of bases as set forth in any of Seq. ID No. 81 + 81.

19. (currently amended) The composition of claim 17-14, wherein the antisense oligonucleotide comprises the sequence a consecutive series of bases as set forth in Seq. ID No. 82.

20. (withdrawn) The composition of claim 14, wherein the therapeutic composition comprises an siRNA that is sequence specific for hsp27.

21. (withdrawn, currently amended) The composition of claim 14 20, wherein the oligonucleotide is an siRNA and the siRNA has backbone modifications to provide resistance against nucleic acid digestion *in vivo*.

Appn No.: 10/605,498

Amendment Dated: October 26, 2005

Reply to Office Action of September 7, 2005

22. (withdrawn) The composition of claim 21, wherein the siRNA has a length of from 16 to 49 nucleotides.

23. (canceled)

24. (withdrawn, currently amended) The composition of claim 22, wherein the siRNA comprises the sequence a consecutive series of bases as set forth in Seq. ID No. 84.

25. (previously presented) The composition of claim 14, wherein the composition is packaged in dosage unit form.

26. (previously presented) The composition of claim 25, wherein the dosage unit form is an injectable solution.

27. (previously presented) The composition of claim 19, wherein the composition is packaged in dosage unit form.

28. (previously presented) The composition of claim 27, wherein the dosage unit form is an injectable solution.

29. (new, withdrawn) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 25.

30. (new, withdrawn) The composition of claim 29, wherein the composition is packaged in dosage unit form.

31. (new, withdrawn) The composition of claim 30, wherein the dosage unit form is an injectable solution.

32. (new, withdrawn) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 36.

33. (new, withdrawn) The composition of claim 32, wherein the composition is packaged in dosage unit form.

34. (new, withdrawn) The composition of claim 33, wherein the dosage unit form is an injectable solution.

35. (new, withdrawn) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 56.

Appln No.: 10/605,498

Amendment Dated: October 26, 2005

Reply to Office Action of September 7, 2005

36. (new, withdrawn) The composition of claim 35, wherein the composition is packaged in dosage unit form.

37. (new, withdrawn) The composition of claim 35, wherein the dosage unit form is an injectable solution.

38. (new, withdrawn) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 57.

39. (new, withdrawn) The composition of claim 38, wherein the composition is packaged in dosage unit form, and wherein the dosage unit form is an injectable solution.

40. (new, withdrawn) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 67.

41. (new, withdrawn) The composition of claim 40, wherein the composition is packaged in dosage unit form, and wherein the dosage unit form is an injectable solution.

42. (new, withdrawn) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 76.

43. (new, withdrawn) The composition of claim 42, wherein the composition is packaged in dosage unit form, and wherein the dosage unit form is an injectable solution.